CALYM and MacroGenics, Partners Against Lymphoma
The CALYM Carnot Institute and MacroGenics, Inc., enter into a partnership to evaluate PD-1 and LAG-3 expression in lymphoma.
Experts at CALYM will work with MacroGenics to evaluate PD-1* and LAG-3* expression in lymphoma samples to better understand potential therapeutic opportunities for MacroGenics’ pipeline candidates, including MGD013, a PD-1 x LAG-3 expression bispecific DART® molecule capable of blocking both checkpoint molecules and currently undergoing phase 1 clinical evaluation.
The CALYM consortium is a leading institution in the study of the mechanism of action underlying these therapeutic strategies in the lymphoma field, at the molecular, cellular, micro-environment and clinical levels. **
The CALYM Institute is uniquely suited to address these translational questions owing to its access to a large collection of lymphoma samples, including tissue microarrays (TMA) from the pathology department of the University Hospital of Lyon (Hospices Civils de Lyon), directed by Prof. Alexandra Traverse-Glehen, a member of the CALYM "Clinical and Experimental Models of Lymphomagenesis" team. Prof. Charles Dumontet, director of the CALYM “Anticancer Antibodies” team, will direct the analysis and provide expert advice.
Results of this collaboration will help design clinical trials in lymphoma maximized for potential patient’s benefit.
*About PD-1 and LAG-3 immune checkpoints
PD-1 protein (Programmed-Death 1), expressed on the surface of activated T cells, is a "negative" regulator of the immune response. Antibodies preventing the binding between PD-1 and its PD-L1 and PD-L2 ligands, which are highly expressed by cancer cells, have shown benefit in the treatment of different cancers, by reactivating the immune response of T cells. LAG-3 (Lymphocyte Activation Gene 3) is also a "negative" regulator of the immune system, inhibiting T-cells as PD-1, and has an effect on regulatory T cells (Treg).
**CALYM bibliographical references
Laurent C. et al. Oncoimmunology. 2015 Apr 2 ;4(8):e1026530. doi : 10.1080/2162402X.2015.1026530
Gravelle P. et al. Oncoimmunology. 2016 Aug 24 ;5(10):e1224044. doi : 10.18632/oncotarget.16680
Rossille et al. Leukemia. 2017 Apr ;31(4):988-991. doi : 10.1038/leu.2016.385.
Michot JM. et al. Eur J Cancer. 2017 Nov ;85:67-77. doi : 10.1016/j.ejca.2017.08.014.
Dercle L. et al. J Nucl Med. 2018 Jan ;59(1):15-24. doi : 10.2967/jnumed.117.193011.
Grasselly C. et al. Front Immunol. 2018 Oct 9 ;9:2100. doi : 10.3389/fimmu.2018.02100.
Houot R. et al. Cancer Immunol Res. 2015 Oct ;3(10):1115-22. doi : 10.1158/2326-6066.CIR-15-0190.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics’ technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.